Publications

5891 Results

SWOG S0410/CTN 0703: A phase II trial of tandem autologous stem cell transplantation (AHCT) for patients with primary progressive or recurrent Hodgkin lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

Authors
E Smith;H Li;JW Friedberg;LS Constine;LM Rimsza;GG Laport;LL Popewell;DG Maloney;M Leblanc;SJ Forman;RI Fisher;P Stiff
Journal / Conference
Blood 124(21):676; American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral;
Year
2014
Research Committee(s)
Lymphoma
Study Number(s)
S0410

Long term follow up of SWOG S0313: Ibritumomab Tiuxetan consolidation after 3 cycles of CHOP plus radiotherapy for high risk limited stage aggressive B-cell lymphoma (http://www.bloodjournal.org/content/124/21/4414)

Authors
DO Persky;TP Miller;JM Unger;CM Spier;S Puvvada;BD Stea;OW Press;LS Constine;KP Barton;M Leblanc;S Smith;RI Fisher;JW Friedberg
Journal / Conference
Blood 124(21):4414; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;
Year
2014
Research Committee(s)
Lymphoma
Study Number(s)
S0313

Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601

Authors
B Till;H Li;S Bernstein;RI Fisher;WR Burack;L Rimsza;JD Floyd;M DaSilva;D Moore;M Leblanc;JW Friedberg
Journal / Conference
Blood 124(21):149, 2014; American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral;
Year
2014
Research Committee(s)
Lymphoma
Study Number(s)
S0601

Double hit lymphoma and double positive lymphoma: subset analyses of MYC positive patients of SWOG S9704

Authors
S Puvvada;P Stiff;M Leblanc;JR Cook;BS Kahl;H Li;L Rimsza;JW Friedberg;SM Smith
Journal / Conference
Blood 124(21):1710; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;
Year
2014
Research Committee(s)
Lymphoma
Study Number(s)
S9704

Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma

Authors
K Dunleavy;MA Fanale;A LaCasce;A Noy;P Fabrizio;S Parekh;JW Hayslip;AS Advani;RS Lord;MJ Lechowicz;R Gaur;JW Leach;A Lucas;S Steinberg;B Kahl;JW Friedberg;RF Little;N Bartlett;W Wilson
Journal / Conference
Blood 124(21):395; American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral;
Year
2014
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/9177

SWOG 1211: Initial report on phase I trial of RVD-Elouzumab for newly diagnosed high risk multiple myeloma (HRMM)

Authors
S Usmani;R Sexton;S Ailawadhi;J Shah;N Callander;T Zimmerman;J Valent;MA Rosenzweig;B Lipe;J Zonder;S Fredette;P Richardson;SV Rajkumar;B Durie;A Hoering;RZ Orlowski
Journal / Conference
Blood 124:4762; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;
Year
2014
Research Committee(s)
Myeloma
Study Number(s)
S1211

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

Authors
S Adams;RJ Gray;S Demaria;L Goldstein;EA Perez;LN Shulman;S Martino;M Wang;V Jones;T Saphner;A Wolff;W Wood;NE Davidson;G Sledge;J Sparano;S Badve
Journal / Conference
Journal of Clinical Oncology 32(27):2959-2967;
Year
2014
Research Committee(s)
Breast
PMID
PMID25071121
PMC
PMC4162494
Study Number(s)
E1199, E2197

Web based pathology assessment in RTOG 98-04

Authors
WA Woodward;N Sneige;K Winter;HM Kuerer;C Hudis;E Rakovitch;BL Smith;LJ Pierce;I Germano;AT Pu;EM Walker;DL Grisell;JR White;B McCormick
Journal / Conference
Journal of Clinical Pathology 67(9):777-780;
Year
2014
Research Committee(s)
Breast
PMID
PMID24989024
PMC
PMC4145412
Study Number(s)
CTSU/R9804

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

Authors
A Zeidan;J-W Lee;T Prebet;P Greenberg;Z Sun;M Juckett;MR Smith;E Paietta;J Gabrilove;HP Erba;MS Tallman;SD Gore
Journal / Conference
British Journal of Haematology 166(3):352-359
Year
2014
Research Committee(s)
Leukemia
PMID
PMID24712482
PMC
PMC4299460
Study Number(s)
E1905

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

Authors
A Zeidan;JW Lee;T Prebet;P Greenberg;Z Sun;M Juckett;MR Smith;E Paietta;J Gabrilove;HP Erba;RP Katterling;MS Tallman;SD Gore
Journal / Conference
British Journal of Haematology 167(1):62-68;
Year
2014
Research Committee(s)
Leukemia
PMID
PMID24995683
PMC
PMC4299466
Study Number(s)
E1905